4 results about "Erk signaling" patented technology

This invention discloses a method for inducing pluripotent stem cells to differentiate into skin keratinocytes and its culture medium, solving problems such as long differentiation cycles, low yields, insufficient purity, and animal-derived contamination in existing technologies. The first stage uses medium I containing FGF2 and tanshinone IIA to promote mesodermal differentiation. The second stage uses medium II containing BMP4, EGF, dexamethasone, and PVA to regulate and synergistically induce the BMP / ERK signaling pathway. The final stage uses medium III for expansion culture, obtaining fibroblasts with a purity >99% within 20 days. This method is non-invasive, simple, and low-cost, with potential for large-scale production. The obtained cells can be used for skin regeneration, disease modeling, drug screening, and clinical treatment, demonstrating significant medical application and industrial transformation value.

The invention discloses an anti-aging two-factor composition based on epigenetic reprogramming and application thereof, and belongs to the technical field of biological medicine. The composition comprises a Wnt pathway small molecule activator Laduvilliub and an ERK pathway activator bFGF, and through synergistic activation of Wnt and ERK signal pathways, epigenetic reprogramming of senescent cells is induced, and senescence-related chromatin open change, histone modification imbalance and DNA methylation clock drift are significantly reversed. At the cellular level, the composition can reverse various senescence phenotypes, namely restoring multiplication capacity, down-regulating expression of senescence-related secretory phenotype factors, relieving DNA damage, improving telomerase activity and telomere length and increasing nucleofibrin. At an individual level (an old mouse model), the composition is injected in the intraperitoneal cavity, so that the cognitive ability and the exercise ability are remarkably improved, the aging pathological characteristics of multiple organs are reduced, and the aging-related gene expression profiles of the organs such as the liver and muscles are reversed. The double-factor composition can be applied to anti-aging drugs, health care products or cosmetics.

The invention discloses a process for affinity separation of active components in inonotus obliquus by using a VEGFR2 extracellular domain and application, and relates to the technical field of active component extraction.The process comprises the steps that eight active components including echinacoside, trilliin, typhaenoside, hederagenin, asiaticoside, lanosterol, betulin and aster ketone are selected; the inhibition effect of the compound on cervical cancer cells is studied. The method comprises the following steps: taking a sample to be detected, taking a detection solution, carrying out lauryl sodium sulfate-polyacrylamide gel electrophoresis and Western blot analysis, determining the protein expression quantity of VEGFR-2 related pathways, and researching the regulating effects of trillioside, betulin, hederagenin and lanosterol on a PI3K / AKT signal pathway, a PLC gamma / ERK signal pathway, Bad protein, Caspase-9 protein and Cleaved Caspase-9 protein of SiHa cells.

In the various aspects and embodiments, the present disclosure provides compositions and methods for treating pancreatic cancer (e.g., pancreatic ductal adenocarcinoma, or PDAC). In accordance with aspects of the disclosure, the composition comprises an aptamer that targets accumulation of the composition to pancreatic cancer cells, and an antisense oligonucleotide that inhibits the expression of an mRNA associated with key signaling pathways that promote proliferation or survival in pancreatic cancer cells, such as the KRAS-RAF-MEK-ERK signaling pathway or RTK-RAS-ERK cascade. Exemplary antisense oligonucleotides described herein target KRAS, including mutant KRAS. Exemplary antisense oligonucleotides described herein target SOS1 and / or SOS2 transcripts.